Valve Choice in Women of Reproductive Age: Timing, Pregnancy, and Lifelong Tradeoffs

Guidelines and much of the literature favor bioprosthetic heart valves in women with pregnancy desire, yet most evidence is restricted to pregnancy and the first decade after surgery, a period when bioprostheses are usually functionally intact, and late structural valve degeneration and reintervention are underrepresented. This review synthesizes data across the life course and examines how time-window bias may magnify early advantages of bioprostheses while obscuring long-term tradeoffs. Evidence suggests that bioprostheses often yield better fetal outcomes and fewer anticoagulation-related complications around pregnancy, whereas beyond 10–15 years, cumulative risks of degeneration, valve-in-valve limitations, and prosthesis–patient mismatch may erode these early benefits. In carefully selected patients, particularly in higher-risk positions such as the mitral valve, mechanical valves can provide superior long-term durability when high-quality anticoagulation and multidisciplinary pregnancy planning are feasible. Individualized decision-making should integrate valve position, anticoagulation capacity, pregnancy timing, patient preferences, and health system resources. Future studies should extend follow-up beyond 15 years, apply standardized definitions of structural degeneration, use competing-risk and modern causal methods, and incorporate decision-analytic modeling to quantify lifetime tradeoffs and support shared decisions.